https://www.apmnews.com/depeche/0/350489/premiere-etude-randomisee-favorable-au-tocilizumab-dans-le-covid-19%2C-en-france
Randomized controlled trial, sample side 129. No paper yet.
Randomized controlled trial, sample side 129. No paper yet.
Quote:
A total of 129 patients were randomized: 65 for usual treatment + tocilizumab, and 64 for usual treatment.
The primary efficacy endpoint, which was the combination of ventilation need or death at 14 days, was significantly reduced with tocilizumab.